Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE In patients with clinical benefit (progressive disease after 8 weeks), ctDNA testing revealed previously undetected mutations in RAS/BRAF (71%) and EGFR (47%), which often emerged polyclonally. 31350822 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 Biomarker disease BEFREE We report 2 patients with BRAF V600 mutant melanoma who were previously treated with anti-PD-1±anti-LAG-3 antibodies and were switched to BRAF/MEK-inhibitors because of progressive disease. 29939877 2019
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE Additionally, the presence of BRAFV600E was tested in peripheral mononuclear blood cells (PBMCs) as well as brain biopsies from LCH-ND patients, and the response to BRAF-V600E inhibitor was evaluated in 4 patients with progressive disease. 29624648 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 Biomarker disease BEFREE In this retrospective multicenter study with 60 patients suffering from inoperable or metastatic melanoma we evaluated the efficacy of re-challenge with a BRAF inhibitor (BRAF2) with or without MEK-inhibition after progressive disease upon previous treatment with a BRAF inhibitor (BRAF1) with or without MEK inhibition. 30344946 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG. 28727518 2017
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE Of 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease). 27105424 2016
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE In the cohort of WDTC with distant metastasis, patients with wild-type BRAF and TERT promoter had a significantly higher response rate after radioiodine therapy (p = 0.024), whereas the BRAF V600E mutation was significantly correlated with progressive disease (p = 0.025). 26857243 2016
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 Biomarker disease BEFREE Despite major advancements in targeted therapy of metastatic melanoma, most patients relapse and show progressive disease after 5-7 months with single inhibition of BRAF or MEK. 25602684 2015
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 Biomarker disease BEFREE Continuation of vemurafenib after PD might be beneficial in some patients because remaining disease might continue to respond to BRAF inhibition. 25980594 2015
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE Moreover, early adaptive responses limit the initial efficacy of BRAF inhibition, leading mostly to incomplete responses that may favor the selection of a sub-population of resistant clones and the acquisition of alterations that cause tumor regrowth and progressive disease. 25344914 2014
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 Biomarker disease BEFREE Although no melanomas had high-level amplification of BRAF, the two patients with progressive disease as their best response had BRAF copy gain in their tumors. 23833299 2013
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.100 GeneticVariation disease BEFREE Six had V600E-positive tumours (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumours containing wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response). 16880785 2006